China: Epigenic Therapeutics, a frontier biotechnology company dedicated to developing next generation gene editing therapy, has raised US$20m in Series Angel and Pre-A funding. Series Pre-A funding is jointly invested by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. Proceeds will be used to validate advances of…
Home Healthcare Markets International Business Funding round-up: Urban Health, CathVision, AIRS Medical, PeakData, Epigenic Therapeutics